Eli Lilly developed Mounjaro and became a market-cap leader during the 2020s.
Eli Lilly markets Mounjaro, whose active ingredient is tirzepatide, for the treatment of type 2 diabetes. Tirzepatide acts on GIP and GLP-1 pathways. The company also markets Zepbound, which uses the same active ingredient for chronic weight management in eligible adults.
Demand for these medicines helped draw intense investor attention to Eli Lilly and the broader obesity-drug market. Market capitalization rose as investors assessed expected sales, clinical results, manufacturing capacity, and future indications. A high valuation does not guarantee that every pipeline drug will succeed.
Eli Lilly was founded in Indianapolis in 1876 by Colonel Eli Lilly. It is distinct from Novo Nordisk, another major company in diabetes and obesity medicines. Mounjaro and Zepbound are brand names, while tirzepatide is the generic name of their active ingredient.